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Abstract 
Objective: To investigate the effects of bone morphogenetic protein-2 (BMP-2) on the prolif-
eration, differentiation and apoptosis of normal human gastric mucosal cells and gastric cancer 
cells.  
Methods: Poorly differentiated gastric cancer BGC823 cells, moderately differentiated gastric 
cancer cells and normal human gastric mucosal epithelial GES-1 cells were independently treated 
with recombinant human BMP-2 or its inhibitor Noggin. MTT assay was performed to detect the 
proliferation, flow cytometry done to measure the cell cycle and apoptosis and immunohisto-
chemistry carried out to determine the expression of cyclin-dependent kinase 4 (CDK4).  
Results: BMP-2 exerted inhibitory effect on the growth of all types of cells and the inhibition 
become more evident with the increase of BMP-2 dose. After treatment with 200 ng/ml BMP-2, 
cancer cells arrested in G1 phase and those in S phase reduced. Gastric cancer cells had higher 
CDK4 expression than GES-1 cells. BMP-2 decreased CDK-4 expression in cancer cells but had no 
influence in GES-1 cells. Noggin conferred promotive effect on the growth of 3 types of cells. In 2 
types of cancer cells, treatment with 2000 ng/ml Noggin significantly increased the proportion of 
cells in S phase but reduced that in G1 phase. However, Noggin did not affect the cell cycle of 
GES-1 cells. The CDK4 expression was markedly increased in 2 types of cancer cells but that of 
GES-1 remained unchanged after treatment with 2000 ng/ml Noggin.  
Conclusions: BMP-2 may inhibit the proliferation of both normal and malignant gastric epithelial 
cells, down-regulate CDK4 expression in gastric cancer cells and arrest gastric cancer cells in 
G1-phase in cell cycle. Through antagonizing BMP-2, Noggin, may accelerate the proliferation of 
gastric cancer cells. Thus, the abnormality of BMP signaling pathway may play an important role in 
the pathogenesis of gastric cancer. 
Key words: Bone morphogenetic protein 2; Noggin; gastric cancer cell; proliferation; cell cycle; 
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Introduction 
Gastric cancer is a malignancy derived from the 
gastric mucosal epithelial cells and accounts for 95% 
of gastric malignancies. Gastric cancer has become a 
common malignancy threatening the human health. 
Thus, to elucidate the pathogenesis has been a focus in 
gastrointestinal research. Loss of response to signals 
for cell growth plays a pivotal role in the occurrence 
and  development  of  tumors.  Cytokines  function  to 
regulate cell growth usually in the G1 phase, and cells 
transiting G1 phase are seldom regulated by signals 
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for  cell  growth.  Among  numerous  cytokines,  trans-
forming growth factor (TGF-β) can inhibit the growth 
of cells in this phase.  
TGF-β  is  a  secretory  polypeptide  superfamily 
and  includes  TGF-β,  activin,  bone  morphogenetic 
proteins (BMPs), etc. To date, a variety of studies have 
been conducted to investigate the role of TGF-β in the 
pathogenesis  of  gastric  cancer.  There  is  evidence 
showing  that  TGF-β1  plays  crucial  roles  in  the  dif-
ferentiation  and  proliferation  of  gastric  cancer  cells 
[1]. The poorer the differentiation of gastric cancer is, 
the  higher  the  TGF-β  expression  is.  The  effect  of 
TGF-β on the cell proliferation is mediated by the re-
ceptors on the cell surface.  
BMPs belong to TGF-β superfamily and distrib-
uted in numerous tissues and cells of human body. 
The  signals  induced  by  BMPs  are  mediated  by  the 
receptors on the target cells and transit into cells to 
exert effect [2-4]. The relationship between BMP and 
gastrointestinal diseases has been a focus in studies on 
gastrointestinal  medicine.  BMP  signal  transduction 
may play crucial role in the differentiation of intesti-
nal mucosal cells and can maintain the phenotype of 
epithelial  cells  [5].  Bone  morphogenetic  protein-2 
(BMP-2) is a member of TGF- superfamily and was 
firstly  found  to  induce  the  ectopic  osteogenesis  [6]. 
BMPs play important roles in the embryonic devel-
opment  and  differentiation  and  proliferation  of  tis-
sues and cells. Different BMPs can exert distinct ef-
fects, which contribute to the cell type, stage of cell 
differentiation and the presence of other cytokines [7]. 
In the development of fetal rats, BMP-4 is expressed in 
the  mesenchymal  cells  in  villi.  In  addition,  normal 
colon  mucosa  of  human  and  adult  rats,  BMP-4  ex-
pression is also noted in the epithelial cells in the stage 
of differentiation and maturation [8]. Hardwick et al 
found that BMP-2 could inhibit the growth of colonic 
epithelial  cells,  promote  their  apoptosis  and  inhibit 
their proliferation in vivo, and expressions of BMP-2, 
BMPR IA, BMPR IB and phosphorylated Smad 1/4 
were found on colonic epithelial cells of human and 
mouse. However, in patients with familial adenoma-
tous  polyposis,  the  BMP-2  expression  was  signifi-
cantly reduced in the microglands [9]. Studies have 
demonstrated that BMP-2 and BMP-6 can accelerate 
the apoptosis of cells in myeloblastoma, multiple my-
eloma and renal carcinoma [10-12]. As compared to 
normal  lung  tissues,  BMP-2  is  highly  expressed  in 
98% of lung cancer [13]. Currently, the role of BMPs in 
the pathogenesis of tumors is still unclear. Previous in 
vivo and in vitro studies  showed BMP-2/4 was re-
lated to the invasion and metastasis of cancer cells, 
and could promote the metastasis of prostate cancer 
and melanoma [14-16] and stimulate the proliferation 
of bladder cancer cells [17]. In prostate cancer patients 
with  bone  metastasis,  the  BMP-7  expression  was 
markedly  increased  [18].  Aoki  et  al  found  that  the 
positive rate of BMP-7 was about 55% in 233 gastric 
cancer patients [19]. Katoh et al for the first time re-
ported the protein and mRNA expressions of BMP-2 
in human gastric cancer cells [20]. Kim et al indicated 
that the BMP-4 expression in gastric cancer patients 
was dramatically higher than that in healthy controls 
and BMP-4 expression was negatively associated with 
the  lymph  node  metastasis  of  gastric  cancer,  which 
suggests BMP-4 might involve in the occurrence and 
metastasis  of  gastric  cancer  [21].  In  our  previous 
study,  histological  examination  showed  the  BMP-2 
expression had a decreasing trend in the progression 
of  chronic  inflammation  of  gastrointestinal  mucosa 
into atypical hyperplasia/intestinal metaplasia (pre-
cancerous lesion) and gastric cancer [22, 23]. This im-
plies that BMP-2 might be related with the biological 
behaviors of gastric mucosal epithelial cells. However, 
the role of BMP-2 in the proliferation and apoptosis of 
normal gastric mucosal cells and human gastric can-
cer cells is still poorly understood.  
In  the  present  study,  normal  gastric  mucosal 
cells (GES-1) and gastric cancer cells (poorly differen-
tiated  BGC823  cells  and  moderately  differentiated 
SGC7901 cells) were treated with recombinant human 
BMP-2 (rhBMP-2) or its inhibitor (Noggin) and MTT 
assay,  flow  cytometry  and  immunocytochemistry 
were  performed  to  detect  the  cell  proliferation,  cell 
cycle and cyclin-dependent kinase aiming to investi-
gate the role of BMP-2 in the pathogenesis of gastric 
cancer.  
Materials and methods  
Cell lines and culture  
BGC823 cells and SGC7901 cells were purchased 
from the Shanghai Institute of Cytobiology in Chinese 
Academy of Sciences and GES-1 cells from the Insti-
tute  of  Oncology  in  Beijing  University.  These  cells 
were  maintained  in  DMEM  (Gibco)  containing  10% 
fetal  bovine  serum  (Hangzhou  Sijiqing  Biotech)  at 
37℃ in a humidified atmosphere  with 5%CO2. Pas-
saging was performed every 72 h. Cells in logarithmic 
phase  were  then  digested  with  0.25%  trypsin  and 
washed in PBS. Cell suspension of designed concen-
tration was prepared with DMEM.  
Detection of cell proliferation by MTT assay 
Cells  in  logarithmic  phase  were  digested  in 
trypin  and  4×104/ml  cell  suspension  was  prepared. 
These  cells  were  seeded  into  96-well  plate  (150 
μl/well) and 6 wells in each group. Three types of Int. J. Med. Sci. 2012, 9 
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cells were independently 2 groups: rhBMP-2 (R&D) 
group  and  Noggin  (PeproTechEC)  group.  In  each 
group, cells were subdivided into 3 subgroups: blank 
control  group,  cell  control  group  and  treatment 
group. In the rhBMP-2 group, cells were treated with 
rhBMP-2 at 50 ng/ml, 100 ng/ml and 200 ng/ml. In 
the Noggin group, cells were treated with Noggin at 1 
ng/ml, 10 ng/ml, 100 ng/ml, 1000 ng/ml and 2000 
ng/ml.  Cells  were  maintained  for  24  h.  When  cell 
adhesion  was  present,  the  culture  medium  was  re-
moved and then 150 μl of rhBMP-2/Noggin at dif-
ferent  concentrations  were  added  to  each  well  and 
culture medium of equal volume was added to con-
trol groups. At 24, 48 and 72 h after treatment, cell 
proliferation was determined. At 4 h before treatment, 
20 μl of MTT solution (Sigma) was added to each well 
followed by incubation for 4 h. After removal of me-
dium, 150 μl of DMSO were supplemented followed 
by shaking for 10 min. Blank control group was also 
set  for  zero  adjustment.  Absorbance  (A)  was  meas-
ured at 570 nm and inhibition rate (IR) was calculated 
as follow: IR = (Acontrol - Aexperiment)/Acontrol×100%.  
Detection of cell cycle by flow cytometry  
Cells  in  logarithmic  phase  were  digested  in 
trypin and cell suspension was prepared. These cells 
were seeded into 6-well plate (2×105/well) and 3 wells 
in each group. Grouping was identical to that above 
but 200 ng/ml rhBMP-2 and 2000 ng/ml Noggin were 
used for treatment. When cell adhesion was present, 
culture medium in each well was removed. Then, 3 ml 
of  rhBMP-2/  Noggin  was  added  to  each  well  and 
culture medium of equal volume supplemented into 
wells in the control group followed by incubation. At 
48 h after incubation, cells were collected by centrif-
ugation (3000 rpm/min for 5 min) and washed in PBS 
(pH: 7.4). The supernatant was slowly removed and 
cells were re-suspended in 1 ml of cold PBS followed 
by centrifugation at 3000 rpm/min for 5 min. Then, 
200 μl of cold PBS were used for re-suspension of cells 
followed by addition of 70% cold alcohol and subse-
quent  incubation  at  4℃  overnight.  The  supernatant 
was  removed  by  centrifugation  and  cells  were 
re-suspended in 1 ml of cold PBS followed by cen-
trifugation. PI working solution (Kagene Biotech Co., 
Ltd) was added followed by incubation at 37℃ for 30 
min.  Flow  cytometry  was  performed  at  an  exciting 
wavelength of 488 nm. 
Detection of apoptosis by flow cytometry 
After rhBMP-2 treatment, apoptosis of 3 types of 
cells  was  determined  by  flow  cytometry.  Grouping 
was similar to that above. Cells were incubated for 48 
h and then digested in EDTA containing trypsin solu-
tion. Cells were collected and washed in PBS (pH: 7.4) 
twice followed by centrifugation at 300 rpm for 5 min. 
Cells were collected and then re-suspended in 500 μl 
of binding buffer followed by addition of 5 μl of An-
nexinV-FITC and 5 μl of Propidium Iodide (Kagene 
Biotech Co., Ltd). Incubation was performed in dark 
at room temperature for 10 min followed by flow cy-
tometry. In the scatter plot, left lower quadrant rep-
resents viable cells, right upper quadrant represents 
cells at middle or late apoptosis phase and necrotic 
cells and right lower quadrant represent cells at early 
apoptosis phase.  
Detection of CDK4 by immunocytochemistry  
The  coverslips  were  treated  with  concentrated 
sulfuric acid overnight and then washed in flowing 
water  and  distilled  water  thrice.  After  drying  and 
sterilization, these coverslips were placed into 24-well 
plate.  Cells  in  logarithmic  phase  were  digested  in 
trypsin  solution  and  6×104/ml  cell  suspension  was 
prepared. These cells were then seeded into 24-well 
plate.  Cells  were  treated  with  rhBMP-2  or  Noggin. 
When cell were adherent to the coverslip, the culture 
medium  was  removed  and  2  ml  of  200  ng/ml 
rhBMP-2 / 2000 ng/ml Noggin were added into each 
well. In the control group, culture medium of equal 
volume  was  supplemented.  Incubation  was  per-
formed  for  72  h  and  coverslips  were  collected  fol-
lowed by detection with a SABC kit (Wuhan Boster 
Biotech  Co.,  Ltd)  according  to  manufacturer’s  in-
structions. In brief, the coverslips were washed in PBS 
(pH: 7.4) thrice and then fixed in 4% formaldehyde for 
15 min. After washing in PBS thrice, coverslips were 
treated  with  hydrogen  peroxide  solution  (30%  hy-
drogen  peroxide:  formaldehyde=1:50)  at  room  tem-
perature for 30 min to inactivate endogenous perox-
ydase. Then, the coverslips were washed in distilled 
water twice and treated with normal goat serum for 
blocking at room temperature for 20 min. The liquid 
on the coverslips was removed and they were incu-
bated with rabbit anti-human CDK4 polyclonal anti-
body  (Wuhan  Boster  Biotech  Co.,  Ltd)  at  4℃  over-
night. In the negative control group, the primary an-
tibody was replaced with PBS. After washing in PBS 
thrice  (2  min  for  each),  the  coverslips  were  treated 
with biotin-conjugated goat anti-rabbit IgG at 37℃ for 
60 min. Following washing in PBS thrice (2 min for 
each), the coverslips were treated with SABC at 37℃ 
for 20 min followed by washing in PBS 4 times (5 min 
for each). DAB (Wuhan Boster Biotech Co., Ltd) was 
employed for visualization at room temperature. Af-
ter  washing  in  distilled  water,  dehydration,  trans-
parentization  and  mounting,  the  cells  on  the  co-
verslips  were  observed  under  a  light  microscope. Int. J. Med. Sci. 2012, 9 
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CDK4 was mainly expressed in the nucleus and posi-
tive  cells  had  brown  nucleus.  Five  fields  were  ran-
domly  selected  at  high  magnification  (395568.00 
um/field)  and  the  percentage  of  area  with  positive 
cells was determined.  
Statistical analysis 
Data were expressed as means ± standard devi-
ation  (means±SD)  and  SPSS  version  13.0  software 
program was employed for statistical analysis. Anal-
ysis of variance was employed for the analysis of pro-
liferation of gastric cancer cells and epithelial cells of 
normal  gastric  mucosa  following  treatment  with 
BMP-2 and/or Noggin. T test was performed for the 
analysis of cell cycle and CDK4 expression following 
treatment with BMP-2 and/or Noggin.  
Results  
Effects of BMP-2 and Noggin on the prolifera-
tion of BGC823 cells, SGC7901 cells and GES-1 
cells 
When compared with control group, treatment 
with rhBMP-2 at different concentrations significantly 
inhibit the growth of three types of cells (P<0.05). In 
addition,  the  IR  increased  with  the  increase  of 
rhBMP-2 concentration. At different time points, the 
proliferation of three types of cells following rhBMP-2 
treatment was dramatically different from that in the 
control  group  (P<0.05).  rhBMP-2  at  lower  than  100 
ng/ml had little influence on GES-1 cells within 24 h, 
but the growth of GES-1 cells were markedly inhibit-
ed at 48 h and 72 h. Noggin could promote the prolif-
eration of three types of cells. When the Noggin con-
centration was ≥1000 ng/ml, the proliferation did not 
increase  with  the  increase  of  Noggin  concentration 
(P>0.05). The most obvious proliferation was found at 
48 h after Noggin treatment and the IR reduced with 
the prolongation of Noggin treatment. Additionally, 
the promotive effect of Noggin on the proliferation of 
BGC823 cells was more obvious than that on the pro-
liferation of SGC7901 cells and GES-1 cells (P<0.05) 
(Figure 1 and 2).  
 
 
Figure 1 Effect of rhBmp-2 at different concentrations on the proliferation of different cells at 48 h after treatment. 
 
Figure 2 Effect of Noggin at different concentrations on the proliferation of different cells at 48 h after treatment. Int. J. Med. Sci. 2012, 9 
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Effects of BMP-2 and Noggin on the cell cycle 
and apoptosis of cells 
The rhBMP-2 treatment was performed for 48 h 
and cells were collected for flow cytometry. Results 
showed the proportion of BGC823 cells and SGC7901 
cells  in  the  G1  phase  was  significantly  increased 
(P<0.05) but that in the S phase dramatically reduced 
(P<0.05). Proportion of cells in the G2 phase remained 
unchanged. These findings suggested most cells were 
arrested in the G1 phase. After Noggin treatment for 
48 h, cells were collected for flow cytometry. Results 
showed the proportion of BGC823 cells and SGC7901 
cells in the S phase was markedly increased (P<0.05) 
but  that  in  the  G1  phase  reduced  dramatically 
(P<0.05). Proportion of cells in the G2 phase remained 
unchanged.  These  findings  suggested  Noggin  in-
creased the DNA synthesis in these cells. Of note, the 
proportion of GES-1 cells in the S phase and G1 phase 
remained  unchanged  following  treatment  with 
rhBMP-2/Noggin  (P>0.05)  (Table  1  and  2).  Three 
types of cells were treated with 200 ng/ml BMP-2 for 
72 h followed by flow cytometry. Results showed the 
proportion of different cells in early apoptosis phase 
remained unchanged after BMP-2 treatment.  
Effects of BMP-2 and Noggin on the CDK4 
expression in BGC823 cells, SGC7901 cells and 
GES-1 cells 
CDK4 expression was found in 3 types of cells. 
The  CDK4  expression  in  BGC823  cells  (5.00±1.16) 
and BGC7901 cells (4.06±0.99) was higher than that 
in  GES-1  cells  (2.82±0.67,  P<0.05).  In  addition,  the 
CDK4  expression  in  BGC823  cells  was  significantly 
higher than that in BGC7901 cells. When compared 
with  control  group,  after  rhBMP-2  treatment,  the 
CDK4 expression in BGC823 cells and SGC7901 cells 
was  markedly  reduced  (2.38±0.99  vs  5.00±1.16; 
2.19±0.80  vs  4.06±0.99;  P<0.05).  After  Noggin  treat-
ment,  the  CDK4  expression  in  BGC823  cells  and 
SGC7901 cells was dramatically increased (2.73±0.73 
vs 4.46±0.96; 2.04±0.90 vs 3.66±0.75, P<0.05). In GES-1 
cells, the CDK4 expression remained unchanged after 
treatment  with  rhBMP-2/Noggin  (P>0.05)  (Figure  3 
and 4).  
Discussion  
TGF-β family is composed of some polypeptide 
growth  factors  with  similar  structure  and  functions 
and  includes  TGF-β,  activin,  BMPs,  etc.  TGF-βnot 
only can affect the proliferation and differentiation of 
some types of cells, but plays important roles in the 
embryonic  development,  formation  of  extracellular 
matrix,  suppression  of  immune  and  inflammation, 
osteogenesis and bone re-construction. For epithelial 
cells, TGF-β can block the transition from G1 phase to 
S  phase  leading  to  cell  growth  arrest  [24].  To  date, 
numerous studies have demonstrated that the TGF-β1 
expression is significantly increased in cancer tissues 
and plasma of gastric cancer patients, which suggests 
TGF-β1 is closely related to the occurrence of gastric 
cancer [25].  
 
Table 1 Cell cycle of 3 types of cells before and after 200 ng/ml rhBmp-2 treatment (means±SD) 
rhBmp-2  G1 phase (%)  S phase (%) 
  BGC823  SGC7901  GES-1  BGC823  SGC7901  GES-1 
-  52.70±5.01  43.30±2.75  60.50±4.53   38.50±1.48  32.80±2.22  29.40±2.80 
+  61.60±2.75*  49.00±2.68*  60.40±3.00  29.60±2.15*  28.20±2.37*  30.00±1.79 
* P<0.05 vs control group 
 
 
Table 2 Cell cycle of 3 types of cells before and after 2000 ng/ml Noggin treatment (means±SD) 
Noggin  G1 phase (%)  S phase (%) 
  BGC823  SGC7901  GES-1  BGC823  SGC7901  GES-1 
-  51.7±2.75  52.2±3.73  60.50±6.80   39.50±4.78  37.3±2.98  29.40±3.43 
+  40.20±2.68*  43.1±2.37*  60.40±5.28  49.6±3.75*  47.4±2.95*  30.0±3.90 
* P<0.05 vs control group Int. J. Med. Sci. 2012, 9 
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Figure 3 CDK4 expression in different cells after rhBMP-2 treatment. Control group: A: BGC823 cells; C: SGC7901 cells; 
E: GES-1 cells; rhBMP-2 treatment: B: BGC823 cells; D: SGC7901 cells; F: GES-1 cells. (×100) 
 
 
 
Figure 4 CDK4 expression in different cells after Noggin treatment. Control group: A: BGC823 cells; C: SGC7901 cells; E: 
GES-1 cells; rhBMP-2 treatment: B: BGC823 cells; D: SGC7901 cells; F: GES-1 cells. (×100) 
 
 
BMPs are a member of TGF-β superfamily and a 
dimmer consisting of two identical or different subu-
nits.  The  homodimer  functions  via  the  p38  mito-
gen-activated  protein  kinase  (MAPK)  signaling 
pathway, but heterodimer involves in the Smad signal 
transduction [7]. BMPs can promote the differentia-
tion of epithelial cells and suppression of BMP-related 
signal transduction has been found to be involved in 
the  occurrence  of  gastric  cancer  [26].  Our  results 
showed rBMP-2 exerted inhibited effect on the pro-
liferation  of  normal  gastric  cells  and  gastric  cancer 
cells,  and  this  inhibition  was  concentra-
tion-dependent. With the increase of rBMP-2 concen-
tration, the inhibition became more evident. In addi-
tion, with the prolongation of rBMP-2 treatment, the 
IR  was  reduced  in  BGC823  cells  but  increased  in 
SGC7901 cells and GES-1 cells, which were consistent 
with previously reported [27]. The progression of cell Int. J. Med. Sci. 2012, 9 
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cycle is regulated by several factors one of which is 
CDK. Our results showed rhBMP-2 treatment could 
reduce  the  CDK4  expression  in  gastric  cancer  cells. 
These findings indicate that rhBMP-2 may block the 
transition  from  G1  phase  to  S  phase  via  inhibiting 
CDK4 expression, which then suppresses the prolif-
eration of gastric cancer cells.  
The  extracellular  BMPs  can  be  antagonized  by 
some  secretory  proteins  including  Cerbarus,  Dan, 
Germlin,  Noggin,  Chordin,  Follistatin,  etc.  These 
proteins can bind to BMPs which blocks the binding 
of BMPs to their receptors. In addition, these proteins 
can  also  affect  the  distribution  of  BMPs  [28].  Our 
findings suggested BMP-2 could inhibit the prolifera-
tion of gastric cancer cells and epithelial cells of nor-
mal gastric mucosa. Following BMP-2 treatment, the 
changes  in  CDK4  expression  were  consistent  with 
findings in MTT assay, both of which demonstrated 
that BMP-2 can inhibit the proliferation of these cells. 
In the present study, Noggin was employed to treat 
gastric  cancer  cells  and  normal  gastric  cells.  After 
treatment with Noggin, an inhibitor of BMP-2, MTT 
assay  and  immunohistochemistry  consistently  indi-
cated that the cell growth was promoted. At 48 h after 
Noggin  treatment,  cells  were  harvested  and  results 
showed the proportion of BGC823 cells and SGC7901 
cells in S phase  was markedly increased.  It is indi-
cated that Noggin treatment can promote the DNA 
synthesis. That is, Noggin can promote the cell pro-
liferation. Following BMP-2 treatment, flow cytome-
try showed the proportion of apoptotic cells remained 
unchanged. Noggin can promote the proliferation of 
gastric cancer cells. The promotion of cell proliferation 
theoretically  serves  as  an  inverse  process  of  DNA 
degradation. Noggin could promote the proliferation 
of BGC823 cells within 24 h and this promotive effect 
became  more  evident  with  the  increase  of  Noggin 
concentration. For SGC7901 cells and GES-1 cells, the 
proliferation  increased  with  the  increase  of  Noggin 
concentration within 48 h. Additionally, the promo-
tive effect of Noggin was the most obvious at 48 h 
after Noggin  treatment, and the proliferation  had a 
reducing  trend  with  the  prolongation  of  Noggin 
treatment. The proliferation of BGC823 cells was more 
evident  than  that  of  SGC7901  cells  and  GES-1  cells 
after Noggin treatment.  
These findings suggest Noggin at a certain con-
centration  can  bind  to  BMP-2  which  changes  the 
BMP-2 expression and affects the influence of BMP-2 
on the cell proliferation. When compared with well 
differentiated gastric cancer and normal gastric epi-
thelial  cells,  the  poorly  differentiated  gastric  cancer 
cells are more sensitive to the changes in BMP-2 ex-
pression. This further confirms that down-regulation 
or loss of BMP-2 expression may affect the differenti-
ation  and  proliferation  of  cells  and  the  changes  in 
BMP-2 expression might be related to the degree of 
cell  differentiation.  In  addition,  our  findings  also 
showed,  when  the  Noggin  concentration  was  ≤100 
ng/ml, the proliferation of cells did not increase with 
the increase of Noggin concentration, and the promo-
tive effect of Noggin on the proliferation was inde-
pendent  of concentration  when  the Noggin concen-
tration was ≥1000 ng/ml. These findings suggest the 
Noggin concentration is linearly related to the prolif-
eration of gastric cancer cells when the Noggin con-
centration is in a certain range. In addition, flow cy-
tometry showed the proportion of BGC823 cells and 
SGC7901  cells  in  the  S  phase  markedly  raised  after 
Noggin  treatment  but  that  in  the  G1  phase  signifi-
cantly  reduced.  This  further  demonstrates  that  the 
binding of Noggin to BMP-2 leads to the inability of 
BMP-2 to bind to corresponding receptors and Nog-
gin  treatment  promotes  the  DNA  synthesis  and  in-
hibit  the  proliferation  of  gastric  cancer  cells.  After 
Noggin treatment, the CDK4 expression in BGC823 
cells and SGC7901 cells was increased. These findings 
were  contrary  to  those  after  BMP-2  treatment.  This 
suggests  endogenous  BMP-2  may  reduce  the  DNA 
synthesis  via  down-regulating  CDK4  expression, 
which  inhibits  the  proliferation  of  epithelial  cells. 
However, this effect of BMP-2 can be antagonized by 
BMP-2 inhibitor. Additionally, exogenous BMP-2 can 
arrest  cells  in  G1  phase  through  down-regulating 
CDK4  expression  suppressing  the  cell  proliferation. 
Noggin can antagonize not only the BMP-2 but other 
members  in  BMP  family  (BMP-4,  BMP-7,  BMP-13). 
Different BMPs exert different effects, and thus, an-
tagonizing  other  members  of  BMP  family  might  be 
also attributed to the promotion of cell proliferation, 
which should be further confirmed in future studies. 
Maloum  et  al  applied  Cre/LoxP  recombinase 
system  to  knockout  BMP-1a  receptor  in  rats.  Their 
results showed the parietal cells were reduced but the 
endocrine  cells  increased  in  the  stomach  [29].  This 
implies that the abnormality of BMP signaling path-
way  in  the  gastric  mucosal  cells  may  render  BMPs 
unable to exert inhibited effect on the proliferation of 
endocrine cells, which might be related to the occur-
rence of gastric cancer. There is evidence showing that 
the serum BMP-2 level in gastric cancer patients was 
higher  than  in  healthy  controls,  and  gastric  cancer 
patients  with  lymph  node  metastasis  had  higher 
BMP-2 level that those without lymph node metasta-
sis  [30,  31].  This  finding  suggests  BMP-2  plays  an 
important role in the occurrence of gastric cancer. Our 
results showed BMP-2 could inhibit the proliferation 
of gastric cancer in vitro. In gastric cancer patients, the Int. J. Med. Sci. 2012, 9 
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BMP-2  signal  transduction  is  abnormal,  which  re-
duces the suppressive effect of BMP-2 on cell prolif-
eration and then compromises the anti-tumor effect of 
BMP-2. Thus, in future studies, the mechanisms un-
derlying  the  abnormal  BMP-2  signaling  pathway, 
which may be helpful to elucidate the role of BMP-2 in 
the pathogenesis of gastric cancer.  
There is evidence showing that TGF- can not 
only inhibit the growth of both normal gastric muco-
sal  cells  and  gastric  cancer  cells  but  promote  their 
apoptosis  [32].  Study  reveals  that  the  apoptosis  of 
smooth muscle cells in pulmonary artery is related to 
BMP [33], and BMP-4 can induce the apoptosis of oral 
mucosal  epithelial  cells  in  vitro  [34].  However,  our 
results  did  not  confirm  the  pro-apoptotic  effect  of 
BMP-2  on  gastric  cancer  cells,  which  may  be  at-
tributed  to  low  BMP-2  concentration  or  absence  of 
involvement of BMP-2 in apoptosis of gastric mucosal 
cells. The specific mechanism is required to be further 
clarified.  
Taken together, our findings primarily demon-
strate that BMP-2 can inhibit the CDK4 expression in 
gastric cancer cells and block the transition from G1 
phase into S phase, which then inhibit the prolifera-
tion of gastric cancer. These findings suggest BMP-2 
plays  important  roles  in  the  occurrence  and  devel-
opment of gastric cancer. Our results provide novel 
clues for the diagnosis and treatment of gastric mu-
cosal diseases and gastric cancer.  
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